The implications of IDH mutations for cancer development and therapy
Mutations in the genes encoding the cytoplasmic and mitochondrial forms of isocitrate
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
dehydrogenase (IDH1 and IDH2, respectively; collectively referred to as IDH) are frequently …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
diagnosis and management of acute myeloid leukemia (AML) in adults are widely …
Epigenetic therapies for cancer
SE Bates - New England Journal of Medicine, 2020 - Mass Medical Soc
Epigenetic Therapies for Cancer | New England Journal of Medicine Skip to main content The
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …
Recent advances in targeted therapies in acute myeloid leukemia
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival
for younger patients over the last several decades has improved nearly sixfold with the …
for younger patients over the last several decades has improved nearly sixfold with the …
Targeting immunometabolism as an anti-inflammatory strategy
The growing field of immunometabolism has taught us how metabolic cellular reactions and
processes not only provide a means to generate ATP and biosynthetic precursors, but are …
processes not only provide a means to generate ATP and biosynthetic precursors, but are …
R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis
Summary R-2-hydroxyglutarate (R-2HG), a metabolite produced by mutant isocitrate
dehydrogenases (IDHs), was recently reported to exhibit anti-tumor activity. However, its …
dehydrogenases (IDHs), was recently reported to exhibit anti-tumor activity. However, its …
Treatment of relapsed acute myeloid leukemia
F Thol, A Ganser - Current treatment options in oncology, 2020 - Springer
Opinion statement Relapse is still a common scenario in acute myeloid leukemia (AML)
treatment and occurs in 40–50% of younger and the great majority of elderly patients. The …
treatment and occurs in 40–50% of younger and the great majority of elderly patients. The …
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase …
CD DiNardo, AC Schuh, EM Stein… - The Lancet …, 2021 - thelancet.com
Background Enasidenib is an oral inhibitor of mutant isocitrate dehydrogenase-2 (IDH2)
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …
proteins. We evaluated the safety and activity of enasidenib plus azacitidine versus …
Advances in the treatment of acute myeloid leukemia: new drugs and new challenges
NJ Short, M Konopleva, TM Kadia, G Borthakur… - Cancer discovery, 2020 - AACR
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in
the past few years, driven largely by translational research into its genomic landscape and …
the past few years, driven largely by translational research into its genomic landscape and …